Sexual dysfunction affects a substantial proportion of the population, with an estimated 40%-45% of adults experiencing a sexual disorder at some point in their lives. Despite the demonstrated ...

Ozempic and other GLP-1 agonist drugs have become an enormously popular way to lose weight. And with generic, much cheaper versions of the medications on the horizon, their use could soon grow even ...

As pharmaceutical companies race to scale synthetic GLP-1s, Evolv is betting that consumers want a natural, orally available version. Evolv co-founder Becca McCarthy saw a massive GLP-1 trend — and ...

Every time Aditi publishes a story, you’ll get an alert straight to your inbox! Enter your email By clicking “Sign up”, you agree to receive emails from ...

With off‑label use surging, it’s virtually impossible to know how many people are currently taking GLP‑1 drugs like Wegovy or Mounjaro, or how many will be prescribed them in the years ahead. The same ...

Ozempic, Wegovy, Mounjaro and other GLP-1s have been touted as miracle drugs with a myriad of health benefits. However, they come at a high environmental cost. The manufacturing of these weight-loss ...

The growth potential in the GLP-1 market could help healthcare stocks soar in value. Competition, however, is likely to be fierce. Many drugs offer comparable weight loss. Healthcare companies have ...

At just over 5 foot, 5 inches, Christie Woodard weighs a lean 125 pounds. She's also open about relying on a low-dose GLP-1 to keep her weight there. She says sometimes people question why she's on ...

With the use of GLP-1 medications on the rise, cardiologists are seeing benefits to heart health, and it might not all be related to weight loss alone. GLP-1 medications, including semaglutide, are a ...

McDonald’s signaled this week it’s looking to better cater to customers on weight-loss drugs — and the name of the game is protein. During a Wednesday earnings call, McDonald’s CEO Chris Kempczinski ...

Hims & Hers Health, Inc. is facing increasing regulatory pressure regarding its compounded GLP-1 offering. The GLP-1 revenue stream has been significant for HIMS, but not the only source of growth.

Human cohort studies and meta-analyses have not shown increased incidence of common differentiated thyroid cancers with GLP-1 receptor agonist exposure. Rodent C-cell tumor signals underpin the boxed ...